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Background: Helicobacter pylori chronic infection is associated with chronic gastritis, peptic ulcer, and gastric cancer.
Cytotoxin-associated gene A (cagA)-positive H. pylori strains increase the risk of gastric pathology. The carcinogenic
potential of CagA is linked to its polymorphic EPIYA motif variants. The goals of this study were to investigate the
frequency of cagA-positive Helicobacter pylori in Mexican patients with gastric pathologies and to assess the association
of cagA EPIYA motif patterns with peptic ulcer and gastric cancer.
Methods: A total of 499 patients were studied; of these, 402 had chronic gastritis, 77 had peptic ulcer, and 20 had
gastric cancer. H. pylori DNA, cagA, and the EPIYA motifs were detected in total DNA from gastric biopsies by PCR. The
type and number of EPIYA segments were determined by the electrophoretic patterns. To confirm the PCR results, 20
amplicons of the cagA 3′ variable region were sequenced, and analyzed in silico, and the amino acid sequence was
predicted with MEGA software, version 5. The odds ratio (OR) was calculated to determine the associations between
the EPIYA motif type and gastric pathology and between the number of EPIYA-C segments and peptic ulcers and
gastric cancer.
Results: H. pylori DNA was found in 287 (57.5%) of the 499 patients, and 214 (74%) of these patients were cagA-positive.
The frequency of cagA-positive H. pylori was 74.6% (164/220) in chronic gastritis patients, 73.6% (39/53) in peptic ulcer
patients, and 78.6% (11/14) in gastric cancer patients. The EPIYA-ABC pattern was more frequently observed in chronic
gastritis patients (79.3%, 130/164), while the EPIYA-ABCC sequence was more frequently observed in peptic ulcer (64.1%,
25/39) and gastric cancer patients (54.5%, 6/11). However, the risks of peptic ulcer (OR = 7.0, 95% CI = 3.3–15.1; p < 0.001)
and gastric cancer (OR = 5.9, 95% CI = 1.5–22.1) were significantly increased in individuals who harbored the EPIYA-ABCC
cagA gene pattern.
Conclusions: cagA-positive H. pylori is highly prevalent in southern Mexico, and all CagA variants were of the western
type. The cagA alleles that code for EPIYA-ABCC motif patterns are associated with peptic ulcers and gastric cancer.
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Chronic Helicobacter pylori infection is etiologically related
to chronic gastritis, gastric ulcers, and gastric cancer [1-4].
Cytotoxin-associated gene A (CagA)-producing strains
seem to induce gastrointestinal disease more frequently
than non-producing strains [5,6]. While the presence of
CagA does not explain the variability in the clinical results,
this oncoprotein is associated with severe gastroduodenal
pathology [7-15]. CagA-positive strains are known to in-
duce more intense gastric mucosal inflammation compared
to cagA-negative strains. This pro-inflammatory potential
of cagA-positive H. pylori could explain its association with
severe atrophic gastritis and gastric adenocarcinoma
[16,17]. The CagA oncoprotein is released within epithelial
cells via a type IV secretion system [18,19]. Upon transloca-
tion, CagA localizes to the internal surface of the plasma
membrane, where it is phosphorylated on C-terminal
variable region tyrosine residues by multiple host Src tyro-
sine kinase family member proteins [20-22]. The phosphor-
ylation motifs are defined by the Glu-Pro-Ile-Tyr-Ala
(EPIYA) sequence and are classified as EPIYA-A, B, C, or D
according to the amino acids that flank these motifs.
Western CagA strains have the A and B segments and 1 or
more C segments. CagA strains from Eastern Asia have the
A, B, and D segments. This explains the size variability of
CagA proteins (range, 120–145 kDa) [3,9,23]. The main
phosphorylation target in CagA is the tyrosine in the
EPIYA-C and EPIYA-D motifs. The phosphorylation level
is proportional to the number of EPIYA-C motifs, and thus,
increased motif numbers increase the pro-inflammatory
and carcinogenic potential of the protein. Phosphorylated
CagA forms complexes with the SHP-2 phosphatase, result-
ing in abnormal signaling. This leads to subsequent cellular
alterations that increase the risk of cells altered by pre-
cancerous genetic changes [3,23-28]. In epithelial cells,
SHP-2 binds more tightly to EPIYA-D than to EPIYA-C.
However, CagA proteins with EPIYA-ABCCC have the
same carcinogenic potential as those with EPIYA-D [25].
Western CagA-producing H. pylori strains with EPIYA-C
sequences are more virulent and carcinogenic than CagA-
producing strains with EPIYA-A and B motifs [15,29,30].
The prevalence of cagA-positive H. pylori is 90–95% in
Asian countries and 50–60% in western countries [3,23].
CagA genotype distribution varies among regions and
ethnic groups. For example, the Amerindian (AM) cagA
allelic variants, which are found in the inhabitants of the
Peruvian Shimaa village, encode CagA isoforms that
contain altered or degenerate EPIYA-B motifs, specifically
ESIYT in AM-I and GSIYD in AM-II. Additionally, the
AM CagA contains attenuated conserved repeats that
are responsible for phosphorylation-independent activity
(CRPIA). The AM strains have attenuated proliferation
and induce low-grade inflammation, resulting in low
virulence and a decreased risk of severe pathology [26,31].CagA is one of the most studied genes worldwide. In
Mexico, the seroprevalence of cagA-positive H. pylori
varies between 40% and 90% in patients with gastric
pathology from different zones throughout the country
[8,32-36]. In patients from Mexico City who presented
gastroduodenal pathology, the EPIYA segments of
cagA-positive strain were of the western type [37]. In
another study conducted in children with abdominal
pain and adults with duodenal ulcers, gastric ulcers, or
non-ulcerous dyspepsia, the identified EPIYA patterns
were ACC, ABC, ABCC, ABCCC, and ABABC [37].
The following sequences were identified in gastric can-
cer and chronic gastritis cases: ABC, ABCC, ABABC,
AABCC, and ABCCC [38]. However, to date, no studies
have been conducted to explore the association between
the type and number of EPIYA segments and severe
gastric pathologies in southern Mexico. The analysis of
the association between the EPIYA-C motif number and
peptic ulcers and gastric cancer, will help to clarify the
relationship between CagA variants and gastric disease
severity in H. pylori-infected Mexican patients. The goal
of this study was to investigate the prevalence of cagA-
positive H. pylori and the EPIYA motif types in the
gastric mucosa of patients with chronic gastritis, peptic
ulcers, and gastric cancer to determine whether the
EPIYA-C motif number is associated with ulcers and
gastric cancer.
In this study, we found a high prevalence of western-
type cagA-positive H. pylori infection, with a predomin-
ant EPIYA-ABCC pattern in Mexican patients with
peptic ulcers and gastric cancer. Interestingly, the pres-
ence of a CagA protein with 2 or more EPIYA-C motifs
was associated with severe gastric pathology.
Methods
Patients
A total of 499 patients were studied. The study sub-
jects were sequentially selected from patients who
suffered from dyspepsia symptoms and had been sub-
jected to upper gastrointestinal tract endoscopy at the
Chilpancingo’s General Hospital “Dr. Raymundo Abarca
Alarcón” or at the State Institute of Oncology in Aca-
pulco, Guerrero, Mexico. The subjects were recruited
between April 18, 2007 and April 19, 2013. Patients in
this study had not received treatment with anti-
microbial agents, proton pump inhibitors, or gastric
pH-neutralizing agents for a month before the endo-
scopic treatment. Patients who received immunosup-
pressive or non-steroid anti-inflammatory treatment
were excluded from the study. Either the patients or
their parents signed an informed consent letter. This
project was approved by the Bioethics Committee of the
Autonomous University of Guerrero and the participat-
ing hospitals.
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Endoscopies were conducted after an overnight fast with a
video processor and a video gastroscope (Fujinon, Wayne,
NJ, USA). Two biopsies from the gastric antrum or body,
the ulcer edge, or the tumor were collected. One biopsy was
immediately fixed in 10% formalin for histological analysis,
while the other was placed in a buffered solution (10 mM
Tris, pH 8.0, 20 mM EDTA, pH 8.0, 0.5% SDS) for the
molecular diagnosis of H. pylori. The latter biopsies were
stored at −20°C until processing.
Histology
The formalin-fixed biopsies were embedded in paraffin,
and 4-μm sections were stained with hematoxylin-eosin
for histological analysis. Histopathological findings were
used to determine each patient’s diagnosis. Gastritis was
classified according to the updated Sydney system.
H. pylori detection
Total DNA was extracted from gastric biopsies according to
the phenol-chloroform-iso-amyl alcohol technique after pro-
teinase K digestion [39]. The specific presence of the H. pyl-
ori 16S rRNA gene was assessed according to the methods
previously described by Román-Román et al. [40]. For all re-
actions, DNA samples from the cagA-positive ATCC43504
and J99 H. pylori strains were used as positive controls. For
negative controls, DNA was substituted with sterile deion-
ized water. All reactions were performed in a Mastercycler
Ep gradient thermocycler (Eppendorf, Hamburg, Germany).
CagA gene amplification
H. pylori 16S rRNA gene-positive samples were subjected
to PCR to detect the cagA gene using the primers de-
scribed previously by Figura et al., [9]. These oligonucleo-
tides amplified a 298-bp fragment within the constant
region [9]. To amplify a 550- to 850-bp region within the
3′ variable region of the cagA gene the primers cag2 and
cag4 described previously by Argent et al., were using
[41,42], Table 1. The reaction mix consisted of 1.7 mM
MgCl2, 0.2 mM dNTPs (Invitrogen, Carlsbad, CA, USA),Table 1 PCR primers used in this study
Primer name and reference Primer sequence (5′to 3′)
cagAF D008 [9] ACAATGCTAAATTAGACAACTTGAGC







cagAEast [42] AGAGGGAAGCCTGCTTGATT5 pmol of each oligonucleotide, 1 U of Platinum® Taq DNA
polymerase (Invitrogen Carlsbad, CA, USA), and 300 ng of
total DNA in a total volume of 25 μl. The following amplifi-
cation conditions were used: 1 cycle at 94°C for 5 min;
30 cycles at 94°C for 40 s, 56°C for 30 s, and 72°C for 50 s;
and a final extension cycle at 72°C for 10 min. The PCR
products were subjected to electrophoresis on a 1.5% agar-
ose gel, followed by ethidium bromide staining and analysis
under an ultraviolet (UV) light. Samples were considered
CagA-positive when at least 1 of the 2 bands was observed.
Amplification of the cagA gene 3′ variable region and
EPIYA motif prediction
Each cagA-positive sample was subjected to 4 PCR reac-
tions to identify the EPIYA motifs. The sense oligonucleo-
tide primer cag28F was used in all 4 reactions, while the
antisense oligonucleotide primers cagA-P1C, cagAP2TA
[41], CagAWest, and CagAEast [42] were used in separate
reactions to amplify the EPIYA-A (~264 bp), B (~306 bp),
C (~501 bp), and D (495 bp) motifs, respectively, Table 1.
All PCR samples were prepared with 0.2 mM dNTPs
(Invitrogen Carlsbad, CA, USA), 1.5 mM MgCl2, 10 pmol
of each oligonucleotide, 1 U of Platinum® Taq DNA
Polymerase (Invitrogen Carlsbad, CA, USA), and 300 ng
of total gastric biopsy DNA in a final volume of 25 μl. The
following amplification conditions were used: 1 cycle at
94°C for 5 min; 35 cycles at 94°C for 1 min, 58°C for 30 s,
and 72°C for 1 min; and a final extension cycle at 72°C for
10 min. The PCR products were separated by electrophor-
esis on a 1.5% agarose gel, followed by ethidium bromide
staining and UV light analysis.
Sequencing and bioinformatics analysis of the cagA gene
3′ variable region
A subset of 20 samples was randomly selected for sequen-
cing to confirm the PCR results. Cag28F and cag4 primers
were used to amplify the variable region and generate ~650
to ~850-bp amplicons. The PCR reaction was conducted in
a 50-μl volume with 15 pmol of each primer, 0.3 mM
dNTPs, 2 mM MgCl2, and 1 U of Platinum® Taq DNAMotif amplied Size (bp)
GA Constant region of the cagA gene 298
AT
cagA 3′ variable region 550 to 850
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The amplification conditions were as follows: 1 cycle at
94°C for 5 min; 30 cycles at 94°C for 40 s, 55.5°C for 30 s,
and 72°C for 50 s; and a final extension cycle at 72°C for
7 min. The PCR products were purified with the Pure-
Link® PCR Purification Kit (Invitrogen Carlsbad, CA,
USA) according to the manufacturer’s instructions. The
purified products were sequenced with the BigDye ter-
minator v1.1 sequencing kit (Applied Biosystems, Foster
City, CA, USA) and analyzed with an ABI PRISM 310
Genetic Analyzer (Applied Biosystems). The nucleotide
sequences were transformed into amino acid sequences
with MEGA v5 software [43]. The ClustalW option within
the MEGA software was used to generate a multiple
amino acid sequence alignment. The partial CagA protein
sequence from the H. pylori strain 43526 (GenBank:
AF001357.1) was used as a reference.
Statistical analysis
Kruskal-Wallis, ANOVA, χ2, and Fisher’s exact test analyses
were used to determine significant differences. Associations
between the presence of H. pylori, CagA, and the EPIYA-C
motif number were determined in multinomial logistic
regression models at a confidence interval of 95%. A
p-value < 0.05 indicated statistical significance. All ana-
lyses were conducted with the Stata v11.1 software
package (StataCorp, College Station, TX, USA).
Results
Population characteristics
Of the 499 studied patients, 402 (80.6%) were diagnosed
with chronic gastritis, 77 (15.4%) with peptic ulcers, and
20 (4%) with gastric cancer. The age of patients ranged
from 11 to 80 years old. The cancer patients were signifi-
cantly older (p < 0.001) than those in the other groups,
and the female gender was predominant in all 3 groups.Table 2 Sociodemographic characteristics in Mexican patients
Diagnosis
Chronic gastritisn = 402




Smoking habit n (%)
No 239 (59.5)
Current smoker or former smoker 163 (40.5)
Alcohol consumption n (%)
No 100 (24.9)
Consumes or consumed 302 (75.1)
Education [median (ranges), years] 12 (6–17)
†ANOVA test; ▀Kruskal-Wallis test; ◊ χ2 test.Education years were significantly different among the
groups (p < 0.001), Table 2.
CagA status of Helicobacter pylori infections
The presence of the H. pylori 16S rRNA gene was detected
in the gastric mucosa samples from 287 (57.5%) patients.
The difference in the infection frequencies according to the
diagnosis was significant (p = 0.037), and a higher prevalence
was observed in gastric cancer patients (70%), Figure 1A.
The H. pylori cagA gene was found in 214 (74%) of the 287
infected patients, Figure 1B. However, no significant differ-
ences in the frequencies of cagA-positive H. pylori were
found among the study groups (p = 0.930). The congruence
between the two PCR assays for determining cagA status
was 88% (Kappa correlation coefficient = 0.8857 p <0.001),
data not shown
EPIYA segments and EPIYA-C motif numbers
The PCR products amplified from cagA-positive samples
showed four electrophoretic patterns that corresponded
to the following combinations of EPIYA motifs: ABC,
ABCC, ABBC, and ABBCCC. The EPIYA-D motif was
not detected, Figure 2.
The EPIYA-ABC segment was detected in 148 (69.2%)
patients, while the ABCC motif was detected in 64 (29.9%)
of the 214H. pylori cagA-positive subjects. The EPIYA
ABBCCC motif was only detected in one patient with
chronic gastritis, while the ABBC motif was only detected in
one patient with gastric cancer, Figure 1C. The EPIYA-ABC
pattern was found in 130 (79.3%) of the 164 cagA-positive
H. pylori patients with chronic gastritis and was more fre-
quent in this group than in ulcer and cancer. CagA-positive
H. pylori with two EPIYA-C motifs was more frequently
detected in patients with ulcers and gastric cancer (64.1%
and 54.6%, respectively), Table 3, Figure 1C. The results were
confirmed by sequencing a ~650- to ~850-bp fragmentwith chronic gastritis, peptic ulcers, and gastric cancer
Peptic ulcern = 77 Gastric cancern = 20 p value
52.8 ± 16.5 58.7 ± 16) 0.0009†
33 (42.9) 9 (45) 0.682◊
44 (57.1) 11 (55)
36 (41.8) 10 (50) 0.096◊
41 (53.2) 10 (50)
22 (28.6) 6 (30) 0.716◊
55 (71.4) 14 (70)











































































































Figure 1 Prevalence of H. pylori, cagA, and EPIYA patterns according to histopathological diagnoses. A) Percentage of patients with H. pylori
infection according to gastric disease. There were statistically significant differences in the prevalence of H. pylori among the study groups (p = 0.037, χ2 test).
B) Percentage of cagA among patients with H. pylori infection. The prevalence of cagA-positive H. pylori was very similar among the study groups (p = 0.930,
χ2 test). C) The prevalence of the different EPIYA patterns in the cagA gene is shown. The EPIYA-ABC and ABCC sequences were differentially distributed
among patients with chronic gastritis, peptic ulcers, and gastric cancer (p = 0.000; Fisher’s exact test).
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domly selected samples. The agreement between the results
of PCR and sequencing was 100%.
Bioinformatic analysis of the CagA amino acid sequence
The cagA DNA sequences from the following amplicons
were analyzed: 9 gastric cancer amplicons (MX02-C,MX21-C, MX22-C, MX05-C, MX12-C, MX03-C, MX08-
C, MX17-C, MX16-C); 9 chronic gastritis amplicons
(MX66-G, MX51-G, MX52-G, MX637-G, MX006-G,
MX44-G, MX43-G, MX45-G, MX392-G) and two peptic
ulcer amplicons (MX204-GU, MX327-GU). An in silico
amino acid prediction was conducted to identify the
EPIYA and CagA multimerization (CM, also known as
Figure 2 Electrophoresis of representative samples with different CagA EPIYA patterns. DNA from representative clinical samples from cagA-positive
H. pylori patients (E, F, G, H) was amplified by EPIYA motif-specific PCR. The PCR products were analyzed on a 1.5% agarose gel. Column 1: 100 bp MWmarker;
E (columns 2–4) EPIYA-ABC; F (columns 5–7) EPIYA-ABCC; G (columns 11–13) EPIYA-ABBC; H (columns 14–16) EPIYA-ABBCCC. DNA from the H. pylori 43504
strain, which contains the EPIYA-ABCCC motif, was used as a positive control. Size of products of EPIYA motifs by PCR-specific: EPIYA A motif (~264 bp), EPIYA
B (~306 bp ), second EPIYA B motif (500 bp), first EPIYA C (501 PB) second EPIYA C motif (~650 bp) and third EPIYA-C (>650 bp).
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ing patterns were found: EPIYA-A with the EPIYA(K/Q)
VNKKK (A/T/V/S)GQ pattern, EPIYA-B with the E(P/S)
IY(A/T)(Q/K)VAKKV(N/T)(A/Q)KI pattern, and EPIYA-
C with the EPIYATIDDLGGP pattern, Figure 3. Two
EPIYA-B motif variants were found; one chronic gastritis
sample (MX44-G) had an ESIYT sequence, while 10 (50%)
of the 20 sequences contained the EPIYT pattern (MX02-
C, MX22-C, MX05-C, MX637-G, MX03-C, MX08-C,
MX327-GU, MX43-G, MX16-C). The following changes
were found among the 16 amino acid residues that com-
prise the CRPIA motif: FPLK(R/K)H(D/G)KVD(D/N)
LSKVG for the first CRPIA motif in the N-terminus of
EPIYA-C, FPLK(R/K)H(D/G)KVDDLSKVG for the sec-
ond CRPIA motif, and FPLKRHDKVDDLSKV for the last
CRPIA motif in the C-terminus. A CRPIA motif was iden-
tified in the N-terminus of one of the two EPIYA-B motifs
in the CagA-containing MX16-C gastric cancer sample.
Within this sequence, the amino acids GKDKGPE were
found in the N-terminus of the EPIYA-A motif (Figure 3).
All CRPIA motifs were of the western type, Figure 3. Nu-
cleotide and predict protein sequences of all strains were
deposited in GenBank, accession numbers [GenBank:
KF800898.1- GenBank:KF800917.1].Association between H. pylori infection, cagA-positive
strains, peptic ulcers, and gastric cancer
H. pylori infection was associated with peptic ulcers
(OR = 1.8; 95% CI = 1.0–3.0) but not with gastric cancer
(OR = 1.9; 95% CI = 0.72–5.1). On the other hand,infection with cagA-positive strains was not associated
with either ulcers or gastric cancer, Table 3.
Association between the EPIYA-C motifs number with
peptic ulcers, and gastric cancer
The presence of the EPIYA-ABCC segment was associated
with peptic ulcers (OR = 7.0; 95% CI = 3.3–15.1; p < 0.001)
and gastric cancer (OR = 5.9; 95% CI = 1.5–22.1; p = 0.008).
The increase in the number of EPIYA-C repeats was also
associated with peptic ulcers (OR = 6.8; 95% CI = 3.2–15.6;
p < 0.001), as well as cancer (OR = 4.5; 95% CI = 1.3-15.9;
p = 0.017), Table 3.
Discussion
Infection with a cagA-positive H. pylori strain is recog-
nized as the most important risk factor for gastric cancer
and is also associated with atrophic gastritis and duo-
denal ulcers [29,44]. Nonetheless, the majority of in-
fected patients do not develop serious diseases.
In the present study, we found that 57.5% of patients
with gastric pathologies were H. pylori-positive, and 74%
of the infecting strains harbored the cagA gene. The global
prevalence of cagA-positive H. pylori, which ranges from
43% to 90%, is in accordance with the previously reported
seroprevalence in a Mexican population with gastric path-
ologies [8,32-36]. However, serology might overestimate
the frequency of H. pylori and cagA-positive strains as it is
unable to differentiate between current and past infec-
tions. The discrepancies in the prevalence of H. pylori can
be explained by differences in the diagnostic method used,
age of patients, geographic area and the environmental
Table 3 Association of H. pylori, cagA and EPIYA-C motif
number with chronic gastritis, peptic ulcer and gastric
cancer
H. pylori
Diagnosis Negative Positive OR CI 95%
G 182 220 1.0 -
PU 24 53 1.8c 1.0-3.0
GC 6 14 1.9 0.72-5.1
Total 212 287
CagA
Negative Positive OR CI 95%
G 56 164 1.0 -
PU 14 39 0.9 0.5- 1.9
GC 3 11 1.2 0.3 – 4.6
Total 73 214
EPIYA motif
ABC ABCC OR IC95%
G 130 33 1.0 -
PU 14 25 7.0a 3.3 – 15.1
GC 4 6 5.9b 1.5-22.1
Total 148 64
Number of EPIYA-C
1 C* ≥2 Cϕ OR IC95%
G 130 34 1.0 -
PU 14 25 6.8a 3.2-15.6
GC 5 6 4.5c 1.3-15.9
Total 149 65
G; chronic gastritis, UP peptic ulcer, CG: gastric cancer. ap < 0.001 ; bp <0.01;
cp < 0.05. * The EPIYA-ABBC was added; ϕ the EPIYA-ABBCCC was added
Note: Only the most frequent EPIYA motifs were considered.
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explanation is that the rate of infection is decreasing [36].
In our study, the prevalence of cagA-positive H. pylori in
patients with chronic gastritis was higher (74.6%) than the
rate reported in 2009 by Paniagua et al. (52.4%) via multi-
plex PCR [45]. In gastric cancer patients, the prevalence
of cagA was higher (78.6%) than the seroprevalence
reported in 2008 by Carmolinga et al. (66.2%) [8]. In this
work, the frequency of H. pylori cagA-positive that we
found was similar to antibodies prevalence in Mexican
subjects and, unlike to other studies, the strengths of our
study are in the sample size and the high sensitivity and
specificity of the methods used to detect H. pylori and
cagA.
Some authors have found an association between CagA
and the severity of gastric pathologies [7,11-14]. It has
been proposed that this relationship might be explained
by the number of EPIYA-C motifs in the protein as these
motifs influence the degree of virulence and oncogenic
potential of cagA-positive H. pylori [7,46]. It is likely thatdetermining the EPIYA motifs in CagA, rather than de-
tecting cagA per se, would be a better marker for assessing
the risk of serious gastric pathology [41,47]. In our study,
100% of the EPIYA motifs identified in CagA were of the
western type, and their distributions among the patholo-
gies were significantly different (p ≤ 0.001). In 69.1% of the
cases, the cagA gene contained an EPIYA-C motif in the
typical ABC sequence, and this was more frequent in
patients with chronic gastritis (79.3%). This result was
similar to that reported by Batista et al. for Brazilian pop-
ulations (70.6% in total of cases and 79.4% in patients with
gastritis), [48] but higher than that found in Colombian
patients by Quiroga et al. (49% in total of cases and 59.6%
in patients with gastriris), [29] and by Acosta et al. (62.3%
in total of cases and 52.6%, in gastritis) [49]. Interestingly,
Rizzato et al. [38] detected the EPIYA-ABC pattern in
82% of Venezuelan and Mexican patients with chronic
gastritis and gastric cancer, without finding frequency
differences between the groups. Reyes-León et al. [37]
found that the ABC sequence was more frequent (50%) in
children from Mexico City with chronic abdominal pain.
These findings emphasize the differences in the geo-
graphic distribution of H. pylori strains, and these differ-
ences might be related to the uneven prevalence of gastric
cancer in the inhabitants of different Mexican regions.
The frequency of cases that harbored cagA-positive H.
pylori with two EPIYA-C motifs was higher in gastric
cancer patients (64%) and thus higher than the frequen-
cies reported by Acosta (27.7%) and Quiroga (35.3%) in
Colombia and by Batista in Brazil (34.6%) [29,48,49]. We
found that the cagA allele that encoded two EPIYA-C
segments was also predominant in patients with peptic
ulcers (54.5%). This frequency is higher than that
reported by Torres in Cuban patients (15.7%) [50]. Un-
expectedly, the only motif with three EPIYA-C repeats
(ABBCCC) was found in a patient with chronic gastritis.
Reportedly, an increase in the number of phosphoryl-
ation sites in the C-terminus of CagA is associated with
the carcinogenic potential of H. pylori [15,37,49]. Thus,
it is likely that those patients with chronic gastritis
infected with a H. pylori strain with cagA gene that
encodes two or more EPIYA-C motifs (21%) are at
higher risk of developing more serious diseases.
The amino acid sequences obtained during a bioinfor-
matics analysis revealed that the alanine-to-threonine sub-
stitution in the EPIYA-B (EPIYT) motif occurred frequently
(10 out of 20 sequences) in the studied groups. These find-
ings are in accordance with those reported by Rizzato et al.
in 2012 for Mexican and Venezuelan subjects with chronic
gastritis and gastric cancer (50% of the B motifs harbored
the EPIYT variant, with no significant differences between
the groups) [38]. ABCC isolates bearing this modification
have also been reported to cause decreased levels of cellular
elongation and IL-8 secretion compared to those that bear
Figure 3 (See legend on next page.)
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Figure 3 Alignment of CagA sequences from patients with gastric disorders. CagA amino acid sequences obtained from nine patients with chronic
gastritis (G), two with peptic ulcer (GU) and nine with gastric cancer (C) are aligned with the CagA sequence from H. pylori reference strain 43526. The
sample number is followed by the histological diagnosis. The EPIYA amino acids are shown in blue. The red lines highlight each EPIYA pattern, and the
green lines underline the CRPIA motifs. Alanine-to-threonine changes (EPIYT) in EPIYA-B are shown in orange. The ESIYT sequence that corresponds to
the proline-to-serine and alanine-to-serine changes in EPIYA-B is shown in pink. An AM-I strain was detected in one patient with chronic gastritis (MX44-G
[GenBank: KF800906.1]. The sample MX16-C [GenBank: KF800911.1] from patient with gastric cancer contain a CRPIA motif in the N-terminus of its second
EPIYA-B. This sequence is unique in that it contain an extra EPIYA-B motif and an extra CRPIA motif, making it difficult to align it with CagA from strain
43526. GenBank accession numbers of each strain in this figure:MX02A-C [KF800917.1], MX66-G [KF800903.1], MX21-C[KF800909.1], MX22-C[KF800908.1 ],
MX51-G[KF800904.1], MX652-G[KF800898.1], MX05-C[ KF800915.1], MX12-C[KF800912.1], MX204-GU[KF800902.1], MX637-G[ KF800899.1], MX006-G
[KF800914.1], MX03-C[ KF800916.1], MX08T-C[KF800913.1], MX44-G[KF800906.1], MX327-GU[KF800901.1], MX43-G[KF800907.1], MX45-G[KF800905.1],
MX392-G[KF800900.1], MX17-C[KF800910.1], MX16-C[KF800911.1].
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Mexican population, the frequency of CagA isoforms with
the EPIYT amino acid sequence in EPIYA-B is associated
with the prevalence of gastroduodenal diseases. However,
the existing epidemiological and experimental studies are
insufficient to further support this hypothesis.
The ESIYT modification in EPIYA-B was identified in
one chronic gastritis sample. This sequence belonged to the
AM-I CagA variant, which has been associated with low H.
pylori virulence in comparison to the western or Asian
strains [26]. However, the AM-I and II CagA variants, such
as those found in indigenous Mexican groups with Amerin-
dian ancestry, show degeneration or elimination in their
CRPIA motifs [26,31,51]. Interestingly, the CagA variants
with the ESIYT sequence found in the present study
contained western-type CRPIA and therefore differed from
the Amerindian variants [31]. A CRPIA sequence in the N-
terminus of the EPIYA-B motif was also detected in a gas-
tric cancer sample. This finding agrees with those reported
by Sicinschi et al., Sgouras et al. and Acosta et al., who
noted that in some CagA variants, the CRPIA segment can
be found in the N-termini of the EPIYA-A and B motifs
[15,49,52]. The localization of the CRPIA motif within
EPIYA-B might result from recombination between H.
pylori strains with different cagA allelotypes or from the
insertion of DNA sequences that contribute to H. pylori
diversification [53,54]. The CRPIA sequences stabilize the
CagA protein, influence its half-life and are associated with
oncoprotein activity in epithelial cells [15]. Thus, our results
highlight the need to evaluate the functional importance of
the EPIYT and ESIYT variants in EPIYA-B. Furthermore,
it is necessary to assess the effects that the observed se-
quence variants and the localization of the CRPIA motifs in
the ABCC pattern exert on CagA activity. It is likely that the
prevalence of some of these variants could explain why the
gastric cancer incidence rates of male and female Mexican
patients (9.4 and 6.7/100,000, respectively) are similar to
those reported in Southeastern Asian countries (10.2 and
4.7/100,000 in men and women, respectively) [55], despite
the differences in the cagA-positive H. pylori prevalence
(90–95% in Japan, Korea, and China; 50–60% in Mexico).The association of cagA polymorphisms with severe
gastric pathologies [7,29,48-50,52] or with pre-cancerous
lesions is controversial [10,15,30,32], and only a few
studies have been conducted in Hispanic populations
with gastric ulcers [50]. This is the first study to investi-
gate the prevalence of cagA variants in southern Mexico.
Our results show that the presence of two or more
EPIYA-C repeats within the cagA gene represents a
higher risk of peptic ulcers and gastric cancer. It is likely
that this increase in the number of EPIYA-C repeats
plays an important role in the development of such dis-
eases in individuals from this particular geographic re-
gion. A total of 51.5% of the samples with two EPIYA-C
repeats came from patients with chronic gastritis. It is
likely that some of these individuals have a higher risk of
cancer development [29] given that the increase in the
number of EPIYA-C motifs increases the CagA phos-
phorylation status and its interactions with cellular pro-
teins that induce epithelial cell elongation, cell turnover,
and pro-inflammatory cytokine production, thus facili-
tating the development of gastric cancer [29,41]. These
findings might also be related to other clinical results.
The virulence factors of H. pylori are important risk
determinants but are not sufficient to induce the full de-
velopment of severe gastroduodenal disease. The host’s
genetic and sociocultural factors also contribute to the
risk of pre-cancerous lesions and gastric cancer [56,57].
Conclusions
In conclusion, the present study shows that cagA-positive
H. pylori infection is highly prevalent in patients from
southern Mexico with chronic gastritis, peptic ulcers, and
gastric cancer. All CagA isoforms were of the western
type. The cagA allele that encodes the EPIYA-ABC pattern
was most frequently observed in chronic gastritis samples,
while the EPIYA-ABCC isoform predominated in peptic
ulcer and gastric cancer samples. CagA variants that
encode two or more EPIYA-C motifs are associated with
peptic ulcer and gastric cancer. Likely, either the EPIYA-
ABCC sequence or patterns with two or more EPIYA-C
motifs are a risk marker for severe gastric pathologies.
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